Proactive Investors - Run By Investors For Investors

Arix Bioscience’s portfolio firm Autolus doses first patient in clinical trial of AUTO4 T-cell lymphoma therapy

PTCL is a form of cancer that arises in areas of the body such as lymph nodes, spleen, the gastrointestinal tract, and skin
Clinical Trial
The first phase of the trial is expected to enrol around 25 patients

Arix Bioscience Plc’s (LON:ARIX) portfolio company, Autolus Therapeutics PLC (NASDAQ:AUTL), has dosed the first patient in a Phase 1/2 clinical trial of its AUTO4 therapy for relapsed or refractory TRBC1-positive peripheral T cell lymphoma (PTCL).

PTCL is a form of cancer that arises in areas of the body such as lymph nodes, spleen, the gastrointestinal tract, and skin when T-cells, white blood cells that fight infection, become abnormal.

READ: Arix Biosciences hails phase I success of investee company Pharmaxis

The first phase of the trial is expected to enrol around 25 patients and evaluate up to three dose levels of the AUTO4 therapy, beginning with a low dose of 25mln AUTO4 cells in cohorts of three to six patients.

If no toxicities are observed, the doses will then escalate to 75mln and 225mln until a recommended dose has been identified, after which up to 30 patients will be enrolled in Phase 2.

Arix also said that data from Autolus’ preclinical programme for AUTO5, a sister to AUTO4 targeting TRBC2-positive lymphoma, was presented at the annual meeting of the American Society of Hematology (ASH) on 2 December.

In a separate announcement, the company added that clinical data from Phase 1/2 trials of Autolus’ AUTO3 treatment had also been presented at the ASH conference.

AUTO3 is a treatment targeting paediatric acute lymphoblastic leukemia, the single most common form of cancer in children, and diffuse large B cell lymphoma, a cancer that affects B-cells which produce antibodies.

The news follows early-stage clinical trial successes from another of the firm’s company’s, Australian firm Pharmaxis (ASX:PXS) in November.

A two-part phase I clinical study revealed Pharmaxis’ drug was safe and there were no adverse reactions.

View full ARIX profile View Profile

Arix Bioscience PLC Timeline

Related Articles

Social media use
April 18 2019
Social first has allowed sites like UNILAD to amass a huge audience with very little capital injection, but what is social first publishing and how is it changing the nature of content and advertising?
An illustration of Ozop's BLIF technique
March 30 2019
A key area of focus for the West Palm Beach, Florida, company is development of balloon lumbar interbody fusion (BLIF) technology
microscope
April 30 2019
The health sciences company has five research and development programs, including gene therapy, its Sol-gel program for nose-to-brain delivery of medical compounds including cannabinoids, as well as non-addictive analgesic peptides as a replacement for morphine, fentanyl and oxycodone

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use